Shin Nippon Biomedical Laboratories Ltd. | Mutual Funds
Mutual Funds that own Shin Nippon Biomedical Laboratories Ltd.
Parvest - Equity Japan Small Cap
1,490,000
3.58%
0
0.51%
07/31/2018
Invesco (Japan) Mid Small Cap Growth Equity Mother Fund
402,098
0.97%
402,098
1%
04/27/2017
Nomura Asset TOPIX ETF Fund (1306)
367,400
0.88%
5,800
0%
07/31/2018
Vanguard Total International Stock Index Fund
235,690
0.56%
0
0%
07/31/2018
Daiwa Asset TOPIX Listed ETF (1305)
180,300
0.43%
1,400
0%
07/31/2018
Nikko Asset Listed Index TOPIX ETF (1308)
165,400
0.4%
0
0%
08/20/2018
DFA Japanese Small Company Series
154,200
0.37%
32,100
0.02%
01/31/2018
Vanguard Developed Markets Index Fund
123,900
0.3%
0
0%
07/31/2018
DFA International Core Equity Portfolio
79,300
0.19%
6,100
0%
04/30/2018
Government Pension Fund - Global (The)
51,600
0.12%
-17,203
0%
12/31/2017
| Address |
St. Luke's Tower, 12/F
Tokyo Tokyo 104
Japan
|
|
Employees
|
- |
| Website |
http://www.snbl.co.jp |
| Updated |
07/08/2019 |
| Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: Preclinical Business, Clinical Business, Translational Research Business, Medipolis Business, and Others. The Preclinical Business segment verifies the efficacy and safety of new drugs using experimental animals and bacterial cells. |
